PP
INDV icon

PDT Partners’s Indivior Pharmaceuticals INDV Stock Holding History

PDT Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.35M Hold
142,792
– – 0.26% 129
2025
Q4 		$5.12M Sell
142,792
-39,387
-22% -$1.2M 0.33% 96
2025
Q3 		$4.39M Sell
182,179
-240
-0.1% -$5.02K 0.28% 131
2025
Q2 		$2.69M Sell
182,419
-42,696
-19% -$497K 0.15% 234
2025
Q1 		$2.15M Buy
225,115
+167,595
+291% +$1.76M 0.15% 238
2024
Q4 		$715K Buy
57,520
+2,596
+5% +$26.7K 0.06% 407
2024
Q3 		$536K Buy
+54,924
New +$643K 0.05% 491

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PDT Partners's INDV Position: Q1 2026 in Review

PDT Partners held its Indivior Pharmaceuticals (INDV) position steady in Q1 2026 at 142,792 shares worth $4.35M. The position accounts for 0.26% of the portfolio, ranked #129.

PDT Partners first reported a position in INDV in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.12M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • PDT Partners held 142,792 shares of Indivior Pharmaceuticals worth $4.35M as of Q1 2026.
  • PDT Partners left its Indivior Pharmaceuticals share count unchanged in Q1 2026.
  • Indivior Pharmaceuticals made up 0.26% of PDT Partners's portfolio in Q1 2026, its #129 holding.
  • PDT Partners first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • PDT Partners's Indivior Pharmaceuticals position peaked at $5.12M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.